Ergomed has announced the appointment of Roy Ovel as chief commercial officer with immediate effect.

He brings to Ergomed over 30 years’ experience in international business development with a number of the leading global CROs. This has included roles with larger CROs such as ICON, TFS and Worldwide Clinical Trials as well as with local, specialist CROs. At TFS International, Roy was responsible for global sales and marketing for more than four years, including leadership of the global marketing team.

Dr Miroslav Reljanović, executive chairman of Ergomed, commented: “Roy brings a wealth of experience to Ergomed. He has a proven track record in building commercial success through an understanding of customer’s needs and delivering growth. I am confident that operating across the Ergomed business he will make a significant contribution to the Company through the services we provide our clients.”

Roy will join Ergomed’s Executive team and will be responsible for global sales and business development activities across the Company’s full services offering. This will include a focus on the benefits to customers of bringing together Ergomed’s expertise in pharmacovigilance and orphan drug development.